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Abstract
Estrogen and structurally related molecules play critical
roles in breast cancer. We reported that resveratrol
(50 MM), an estrogen-like phytosterol from grapes, acts
in an antiestrogenic manner in breast cancer cells
to reduce cell migration and to induce a global and sus-
tained extension of actin structures called filopodia.
Herein, we report that resveratrol-induced filopodia for-
mation is time-dependent andconcentration-dependent.
In contrast to resveratrol at 50 MM, resveratrol at 5 MM
acts in a manner similar to estrogen by increasing
lamellipodia, as well as cell migration and invasion.
Because Rho GTPases regulate the extension of actin
structures, we investigated a role for Rac and Cdc42 in
estrogen and resveratrol signaling. Our results demon-
strate that 50 MM resveratrol decreases Rac and Cdc42
activity, whereas estrogen and 5 MM resveratrol in-
crease Rac activity in breast cancer cells. MDA-MB-231
cells expressing dominant-negative Cdc42 or dominant-
negative Rac retain filopodia response to 50 MM res-
veratrol. Lamellipodia response to 5 MM resveratrol,
estrogen, or epidermal growth factor is inhibited in cells
expressing dominant-negative Rac, indicating that
Rac regulates estrogen and resveratrol (5 MM) signal-
ing to the actin cytoskeleton. These results indicate
that signaling to the actin cytoskeleton by low and high
concentrations of resveratrol may be differentially
regulated by Rac and Cdc42.
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Introduction
Estrogen and structurally related selective estrogen recep-
tor modulators (SERMs) such as phytoestrogens are highly
relevant to breast cancer promotion, prevention, and ther-
apy. In addition to signaling by nuclear estrogen receptors
(ERs) to facilitate transcriptional regulation, estrogen also
induces rapid signaling through cell surface receptor net-
works. Numerous studies have demonstrated that plasma-
membrane ERs are activated by estrogen to crossactivate
tyrosine kinase–type cell surface receptors such as epider-
mal growth factor receptor (EGFR), as well as G proteins and
G protein–coupled receptors [1]. Such rapid estrogen sig-
naling has recently been implicated in the regulation of cyto-
skeletal dynamics and in the modulation of cell migration
and invasion in endothelial, breast cancer, and endometrial
cancer cells [2–5].
Resveratrol (trans-3,4V,5-trihydroxystilbene), a phytoestro-
gen present in grape skin and red wine, can bind to and acti-
vate ERa and ERb and has mixed agonist/antagonist effects
[6,7]. Resveratrol can exert biphasic effects where low con-
centrations are estrogenic and high concentrations are anti-
estrogenic [8–10]. High concentrations of resveratrol have
antioxidant, proapoptotic, antigrowth, anti-inflammatory, anti-
angiogenic, and anti-invasive effects. Therefore, resveratrol is
considered to be a cancer-preventive agent [11–13]. In addition
to a preventive role in the initiation and promotion of cancers,
resveratrol may have potential as a metastasis-preventive
agent. Resveratrol has been demonstrated to reduce hepatoma
cell invasion in vitro through hepatocyte growth factor signaling
and to reduce in vivo hepatoma and Lewis lung carcinoma
invasion in mice [14,15]. Moreover, oral administration of
resveratrol decreased metastatic invasion in a mouse model
of melanoma [16]. Another recent study indicated that res-
veratrol may act as a chemopreventive agent of spontaneous
mammary tumor formation and may reduce metastasis in a
HER2 transgenic mouse model [17].
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In vitro studies, including our work, have shown that
resveratrol at 50 mM significantly inhibits the migration and
invasion of endometrial and breast cancer cells [2,18–21].
We reported that high concentrations of resveratrol can act
in an antiestrogenic manner to inhibit cell migration and the
formation of lamellipodia in the presence of estrogen [2].
These cellular effects of resveratrol may be exerted through
modulation of ER-responsive gene transcription and rapid
signaling by cell surface receptor crosstalk. Resveratrol has
been shown to rapidly modulate mitogen-activated protein
kinase (MAPK), focal adhesion kinase (FAK), and phospho-
inositide 3-kinase (PI3-K)/Akt activity through ER-dependent
and ER-independent pathways [2,9,10,22,23]. These sig-
naling cascades are all relevant to the proliferation, motility,
and survival processes that determine metastatic efficiency.
The reported inhibition of matrix metalloproteinase (MMP)
expression by resveratrol may also be a potential mode for
resveratrol to regulate cancer cell invasion [20,24].
During metastasis, the actin cytoskeleton of invading
cells is remodeled by molecular mechanisms common to all
migrating cells, which involve the protrusion of cell surface
actin structures such as filopodia and lamellipodia and the
assembly of dynamic focal adhesions with the extracellular
matrix (ECM) [25]. Filopodia are not essential for cell migra-
tion and are considered to function as environmental sensors
that can contribute to cell migration by being converted
to lamellipodia (actin structures central to forward migration)
during growth factor receptor signaling [26,27]. We and
others have shown that estrogen acts in a manner similar to
EGF (a promoter of cell migration and invasion) in cancer
cells to extend leading-edge lamellipodia with associated
focal adhesions and to increase cell migration [2,3,28]. We
also reported that resveratrol (50 mM) acts in a manner
opposite to estrogen by the rapid modulation of the actin
cytoskeleton to induce a global and sustained array of
filopodia, decrease in focal adhesions, and inhibition of FAK
activity resulting in reduced cell migration [2]. We have
extended these results in the present study to analyze the
role of key signaling intermediates of the Rho family of
GTPases (Rac and Cdc42) in estrogen and resveratrol
signaling to the actin cytoskeleton. Rho, Rac, and Cdc42
coordinately regulate the actin cytoskeleton and focal adhe-
sion turnover during cell migration and may thus impact
breast cancer metastasis [26,29]. Among Rho GTPases,
Cdc42 has been specifically implicated in filopodia formation,
whereas Rac regulates lamellipodia [26].
As a first step toward elucidating the molecular mecha-
nisms of estrogen and resveratrol on the actin cytoskeleton,
we investigated the role of Rac and Cdc42 in estrogen and
resveratrol signaling. We report that resveratrol exerts a
concentration-dependent effect on the actin cytoskeleton.
Resveratrol at 5 mM acts in a manner similar to estrogen to
promote Rac activity and lamellipodia formation, whereas
resveratrol at 50 mM inhibits Rac and Cdc42 activity and
lamellipodia formation. These data indicate that estrogen
and low concentrations of resveratrol may promote breast
cancer metastasis, whereas high concentrations of resvera-
trol may prevent breast cancer metastasis.
Materials and Methods
Cell Culture
MDA-MB-231 human breast cancer cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum at 37jC in 5% CO2.
Cells were made quiescent by starvation in serum-free
phenol red–free DMEM for 24 or 48 hours.
Migration Assay
Migration assays were conducted as described in
Baugher et al. [30]. Cells were serum-starved in phenol
red–free DMEM for 24 hours and seeded at 1  105 cells/
chamber in the upper well of Costar wells (BD Biosciences,
Bedford, MA) containing membranes with 8-mm-diameter
pores. Dimethyl sulfoxide (DMSO; 0.5%) in DMEM (control
vehicle), 17b-estradiol (Sigma, St. Louis, MO), EGF (Upstate
Biotechnology, Lake Placid, NY), or resveratrol (LKT Labo-
ratories, St. Paul, MN) was added as a chemoattractant to
the bottom well for 8 hours. Cells on the upper surface of
the membrane were removed, and cells that had migrated
to the underside of the membrane were fixed in cold meth-
anol, stained with propidium iodide, and quantified.
Invasion Assay
Cells were handled in the same manner as a migration
assay, except that quiescent cells were placed in Matrigel-
coated invasion chambers (BDBiosciences). The bottomwell
contained DMSO (vehicle), estrogen, or resveratrol. The
number of cells that migrated through the Matrigel matrix
after 24 hours of incubation were fixed, stained with pro-
pidium iodide, and quantified relative to control.
Fluorescence Microscopy
Fluorescence microscopy was conducted as described by
Azios andDharmawardhane [2]. Quiescent cells were treated
with vehicle (DMSO), estrogen, EGF, or resveratrol. Cells
were immediately fixed (3.7% formaldehyde), permeabilized
(0.2% Triton X), and stained with rhodamine phalloidin
(Molecular Probes, Carlsbad, CA) to visualize F-actin. The
actin structures of cells in 20 microscopic fields per treat-
ment were counted for at least three separate experiments.
Digital images of microscopic fields were enlarged with
Adobe Photoshop (Adobe Systems, Inc., San Jose, CA)
and counted by two independent investigators, where one
investigator was uninformed of the treatments. Data are
expressed as mean ± SEM. For images of cells invading
Matrigel-coated Transwell membranes, Z-series of Tracker
Green (Molecular Probes)–loaded cells were collected with a
Leica TCS SP2 AOBS confocal microscope (Leica, Wetzlar,
Germany) with an Ar laser at 488 nm. XZ sections were
reconstructed using ImageJ (W. S. Rasband; US National
Institutes of Health, Bethesda, MD).
Rac and Cdc42 Activity Assay
Rac and Cdc42 activities were determined as described
by Baugher et al. [30]. Quiescent cells were lysed following
vehicle (DMSO), EGF, estrogen, or resveratrol treatment,
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and active Rac or active Cdc42 was pulled down using
GST–p21-activated kinase (PAK)–Cdc42/Rac interactive
binding (CRIB) or GST–Wiscott Aldrich Syndrome Protein
(WASP)–CRIB fusion proteins (Cytoskeleton, Denver, CO),
respectively. Proteins were subjected to Western blot analy-
sis for Rac or Cdc42 with specific antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) on 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels. Positive
bands were imaged and quantified using VersaDoc system
and Quantity One software (Bio-Rad, Hercules, CA). Rac or
Cdc42 activity was determined as the amount bound to
the PAK–CRIB domain or the WASP–CRIB domain as a
function of total Rac or Cdc42 in a cell lysate.
Creation of Stable Transfectants
The construction of MDA-MB-231 cells stably express-
ing dominant-negative Rac or Cdc42 mutants was con-
ducted as described by Baugher et al. [30]. Rac1(T17N) or
Cdc42(T17N) myc-tagged constructs in pIRES.neo vector
(Clontech, Palo Alto, CA) or control (vector alone) were
transfected into MDA-MB-231 cells by standard methods.
Stable transfectants were isolated by selection in 1 mg/ml
G418 (Cellgro, Hendon, VA) and maintained in 0.1 to 0.5 mg/
ml G418. Positive clones were determined according to
myc expression by Western blot analysis using anti-myc
antibody (Upstate Biotechnology) and were verified by anti-
myc immunofluorescence microscopy.
Statistical Analysis
Data are expressed as mean ± SEM. P values were
calculated with Student’s unpaired t tests (Welch-corrected,
when necessary) using Microsoft Excel (Microsoft, Redmond,
WA) or with one-way analysis of variance using Tukey-Kramer
multiple comparisons test and InStat3. P values were con-
sidered significant at V .05.
Results
Estrogen and Resveratrol Modulate Breast Cancer Cell
Migration and Invasion
Because directed cell migration is a prerequisite for me-
tastasis, we assessed the effect of estrogen or resveratrol on
cell migration using Transwell migration assay. Previously,
we have reported that, compared to control, estrogen and
EGF treatments both significantly increased cell migration,
whereas resveratrol (50 mM) significantly decreased cell
migration [2]. Herein, we have extended this study to dem-
onstrate a concentration-dependent effect of resveratrol on
directed cell migration. As in our earlier report [2], 50 mM
resveratrol inhibited cell migration by f 30% compared
to control. Estrogen exerted an effect opposite to that of
50 mM resveratrol by increasing cell migration by two-fold
compared to control. Interestingly, 5 mM resveratrol acted in
a manner similar to estrogen by significantly increasing cell
migration (Figure 1A).
Recent reports have demonstrated a 40% to 60% 50-mM
resveratrol– induced inhibition of cervical cancer cell inva-
sion through Matrigel and of MCF-7 breast cancer cells
through fibronectin or collagen matrices [18,20,21]. We have
confirmed these results through observations of a f 40%
decrease in MDA-MB-231 cell invasion across a Matrigel
matrix in response to 50 mM resveratrol and a f 1.6-fold
increase in invasion in response to estrogen or 5 mM res-
veratrol. The response of invading cells to estrogen or res-
veratrol at 5 mM was significantly different from the response
to resveratrol at 50 mM (P < .01), but not from each other
(Figure 1B). Figure 1C is a representative confocal micro-
graph of interfaces between the Matrigel matrix and the
Figure 1. Effects of estrogen or resveratrol on cell migration and on the
invasion of MDA-MB-231 cells. (A) Cell migration. Quiescent cells were placed
on the top well of Transwell chambers in a serum-free medium using the
following as chemoattractants on the bottom well for 8 hours: DMSO control
(Veh), 10 nM estrogen (E2), or 5 or 50 M resveratrol (Res). The number of
cells that migrated through the membrane of the top well was quantified rela-
tive to control. Data are quantified from an analysis of 25 microscopic fields
per treatment from six experiments and expressed as mean relative cells
migrated ± SEM. *Statistical significance from control vehicle at P < .05. (B)
Invasion. Quiescent cells were placed on the top well of Transwell chambers
where the membrane was coated with Matrigel. The bottom well con-
tained DMSO (Veh), 10 nM estrogen (E2), or 5 or 50 M resveratrol (Res). The
number of cells that migrated through the Matrigel matrix after 24 hours of
incubation was quantified and made relative to control. Data are quantified
from an analysis of 25 microscopic fields per treatment from four experi-
ments and expressed as mean relative cells migrated ± SEM. *Statistical
significance from control vehicle at P < .05. (C) Cells invading through the
Matrigel matrix. Representative images of MDA-MB-231 cells invading the
interface (f 30 M) of the Matrigel matrix and the membrane of the top well
in a Transwell chamber are shown. Left: Cells in response to 5 M resveratrol
(Res) on the bottom well. Right: Cells in response to 50 M resveratrol (Res)
on the bottom well.
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membranes of top wells of Matrigel-coated invasion cham-
bers, where the bottom well contained either 5 or 50 mM
resveratrol. This figure illustrates the chemotactic response
of MDA-MB-231 cells to 5 mM, but not to 50 mM, resveratrol.
Estrogen and Resveratrol Modulate the Actin Cytoskeleton
of Breast Cancer Cells
To investigate the structural mechanism for the effect of
resveratrol on directed migration, we monitored the effect of
estrogen or 5 or 50 mM resveratrol on the actin cytoskeleton.
Our published data show that resveratrol (50 mM) treatment
resulted in a dynamic and sustained global extension of
filopodia [2]. Therein, we hypothesized that an unpolarized
filopodia response to 50 mM resveratrol was responsible
for resveratrol-induced inhibition of cell migration. We have
observed that 50 mM resveratrol can induce unpolarized
filopodia, regardless of whether MDA-MB-231 cells were
in the serum (1% or 10%) or in the ECM environment, as
observed by plating cells on glass, Matrigel (both in 2D and
3D cultures), laminin, or collagen IV (data not shown). In all
environments, resveratrol-induced filopodia were sustained
up to 8 hours, indicating that this response may be involved
in the resveratrol-induced inhibition of migration. We have
also analyzed the actin cytoskeleton of cells that were left
behind on the Transwell membrane after an 8-hour migration
assay and Matrigel invasion assay, and we have observed
that those cells had the expected morphology of numerous
unpolarized filopodia (data not shown).
To determine the concentration dependence of resveratrol
effects on the actin cytoskeleton, we stimulated quiescent
MDA-MB-231 cells with a range of resveratrol concentra-
tions. As shown in Figure 2, A and B, the unpolarized filo-
podia response peaked at 50 mM resveratrol. Resveratrol at
5 and 10 mM did not induce a significantly different filopodia
Figure 2. Reorganization of the actin cytoskeleton in response to resveratrol. (A) Quiescent MDA-MB-231 cells were treated with vehicle (DMSO), EGF (50 ng/ml),
estrogen (0.1 M; top panel), or resveratrol at 5, 50, or 100 M (bottom panel) for 10 minutes, then fixed and stained for F-actin. Results shown are representative
of at least 100 cells/treatment (original magnification, 600). Arrowheads indicate filopodia; arrows indicate lamellipodia. (B) The mean filopodia number per cell
was quantified from at least 50 cells/treatment in response to vehicle (Veh) or various concentrations of resveratrol (Res). Treatments denoted by the same letter
indicate no significant difference between those treatments. Treatments denoted by different letters indicate a significant difference between those treatments at P <
.05. (C and D) Cytoskeletal structures in response to 5 or 50 M resveratrol as a function of time. Quiescent MDA-MB-231 cells were treated with DMSO vehicle
(Veh) or 5 or 50 M resveratrol (Res), then fixed and stained for F-actin at various times following treatment. (C) Number of filopodia per cell. (D) Number of
lamellipodia per cell.
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response from vehicle at 10 minutes. Similar to estrogen
and EGF, resveratrol at 5 mM initially induced filopodia at 1
to 2 minutes following treatment. However, these filopodia
appeared to be reorganized to form lamellipodia in 5 minutes
(data not shown). Resveratrol at 50 and 100 mM significantly
induced filopodia compared to treatments with vehicle and
5 mM resveratrol (all P < .01). In contrast, 5 mM resveratrol
acted in a manner similar to estrogen and EGF, and in-
duced cell polarization and the formation of leading-edge
lamellipodia—structures that have been implicated with di-
rected cell migration in response to EGF [25].
Next, we monitored resveratrol effects on the actin cyto-
skeleton as a function of time. As expected with a rapid
signaling response, 50 mM resveratrol induced filopodia at
2 minutes, with a peak response at 10 minutes. This re-
sponse was sustained until 60 minutes following treatment
(Figure 2C). Resveratrol at 5 mM or vehicle did not induce a
filopodia response. However, 5 mM resveratrol increased
lamellipodia at 5 minutes following treatment, and this re-
sponse was linear from 10 to 60 minutes following treatment.
Conversely, 50 mM resveratrol or vehicle did not induce
lamellipodia at any time point (Figure 2D).
Estrogen and Resveratrol Modulate Cdc42 Signaling
to the Actin Cytoskeleton
Our data demonstrate that ERb(+) breast cancer cells
extend filopodia in response to 50 mM resveratrol (Figure 2)
[2]. The Rho family GTPase Cdc42 has been shown to
regulate filopodia and cell polarization toward chemo-
attractants such as EGF during directed cell migration [31].
Therefore, we monitored the Cdc42 activity of breast cancer
cells in response to estrogen or resveratrol by a pull-down
assay using a GST fusion protein to the Cdc42–GTP binding
domain of WASP, a downstream effector of Cdc42. As
expected, bradykinin, a cytokine known to specifically in-
duce filopodia through Cdc42 [32], activated Cdc42 in
MDA-MB-231 cells at 5 and 10 minutes (Figure 3A). How-
ever, estrogen or resveratrol at 5 mM did not affect Cdc42
activity. Quantification of these data demonstrates that es-
trogen reduced Cdc42 activity, although it was not signifi-
cantly different from control vehicle at any time point for
resveratrol at 5 or 50 mM (Figure 3, B and C). Cdc42 activity
in response to 5 mM resveratrol was not significantly dif-
ferent from control vehicle either. Conversely, 50 mM res-
veratrol at 10 minutes significantly inhibited Cdc42 activity
by f 70% compared to control (P < .004). Resveratrol at
50 mM inhibited Cdc42 activity starting as early as 2 min-
utes following treatment and continued to inhibit until 30 min-
utes (Figure 3, B and C).
The Rho family GTPase Cdc42 is known to specifically
regulate filopodia formation [26]; however, we found that
50 mM resveratrol, which induced a filopodia response,
inhibited Cdc42 activity. To further investigate the role
of Cdc42 in resveratrol action, MDA-MB-231 cells were
transfected with a bicistronic vector containing myc-tagged
dominant-negative Cdc42(T17N) cDNA and stable clones,
which were selected according to neomycin resistance and
myc-Cdc42 expression (Figure 4A).
When cells expressing a control vector were treated with
bradykinin or resveratrol, they induced af 2-fold (P < .001)
and af 2.5-fold (P < .0001) significant increase in filopodia,
respectively. Vehicle-treated cells expressing Cdc42(T17N)
produced f 44% less filopodia than vehicle-treated cells
expressing vector alone (P < .001). These Cdc42(T17N)
cells were completely unresponsive to bradykinin—a posi-
tive control for filopodia [32]. There was a significant differ-
ence in resveratrol-induced production of filopodia between
the control vector and Cdc42(T17N) (P < .0001). However,
Cdc42(T17N)–expressing cells still demonstrated a sig-
nificant f 2-fold increase in filopodia in response to 50 mM
resveratrol when compared to Cdc42(T17N) cells treated
with vehicle (P < .0001; Figure 4, B and C). Comparing this
two-fold response in resveratrol-treated Cdc42(T17N) cells
to the 2.5-fold response in resveratrol-treated control vector
cells indicates that resveratrol may not be signaling through
Cdc42 alone to induce filopodia.
Estrogen and Resveratrol Modulate Rac Signaling
to the Actin Cytoskeleton
The Rho GTPase Rac regulates the organization of poly-
merized actin into leading-edge lamellipodia during directed
cell migration [31]. Because our data demonstrate that es-
trogen and resveratrol induce cell surface actin structures (Fig-
ure 2), we investigated a role for Rac in estrogen-mediated
and resveratrol-mediated actin cytoskeletal rearrangement.
Figure 2. (continued)
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Endogenous Rac activity was analyzed in response to EGF
(positive control), estrogen, or resveratrol at 5 or 50 mM. As
shown in Figure 5, EGF activated Rac at 10 minutes following
stimulation of MDA-MB-231 cells. Interestingly, estrogen acti-
vated Rac at 0.1 mM at 10 minutes following treatment
at the same conditions that induce a lamellipodia response.
Both EGF and estrogen significantly increased Rac activity
by f 2-fold compared to control (P < .01 and .007, respec-
tively). Similarly, 5 mM resveratrol significantly increased Rac
activity byf 3-fold compared to vehicle (P < .05) at 10minutes
and was not significantly different from EGF or estrogen. This
increase in Rac activity was observed starting at 5 minutes
following resveratrol treatment and continued until 60minutes.
Resveratrol at 50 mM, however, significantly inhibited Rac
activity compared to control at 10 minutes (P < .007) follow-
ing addition. This inhibitory effect was observed from 5 to
60 minutes (Figure 5B). We have obtained similar results
using ERa(+) ERb(+) MCF-7 cells where estrogen and 5 mM
resveratrol increased Rac activity (data not shown). These
data indicate that in ER(+) breast cancer cells, a low concen-
tration of resveratrol acts in a manner similar to estrogen
and EGF (a known chemotactic ligand) by activating Rac,
whereas a higher concentration of resveratrol is inhibitory.
To further investigate a role for Rac in estrogen and
resveratrol signaling to the actin cytoskeleton, we created
MDA-MB-231 cells stably expressing a myc-tagged
dominant-negative Rac1 (Rac1(T17N)). Stable clones were
selected by neomycin resistance and expression of myc-
Rac (Figure 6A). Our laboratory has previously demon-
strated that expression of Rac(T17N) inhibits lamellipodia
extension, invasion, and metastasis in metastatic breast
cancer cells [30]. Quiescent cells expressing the control
vector or Rac1(T17N) were stimulated with vehicle, EGF,
estrogen, or 5 or 50 mM resveratrol. As expected, EGF
treatment resulted in a dramatic increase in lamellipodia com-
pared to vehicle in control cells (P < .0001), and estrogen in-
duced a similar increase in lamellipodia in control cells (P <
.0001). Resveratrol at 5 mM induced a slightly less but sig-
nificant (f 10-fold) increase in lamellipodia in control cells.
Lamellipodia responses to EGF, estrogen, or resveratrol
(5 mM) were completely blocked by the expression of a
dominant-negative Rac1 (Figure 6, B and C).
Figure 3. Cdc42 activity of MDA-MB-231 cells in response to estrogen or resveratrol. Quiescent cells were lysed immediately after treatment with compounds for
the indicated times, and WASP–PBD–GST beads were used to pull down active GTP-bound Cdc42. Active and total Cdc42 levels were detected by Western blot
analysis with anti-Cdc42 antibody. (A) Quiescent MDA-MB-231 cells were treated for 10 minutes with DMSO (0) or for 2, 5, or 10 minutes with 400 ng/ml bradykinin
or 0.1 M estrogen (E2) and used for pull-down assays to determine endogenous Cdc42 activity. Representative Western blot analyses of active and total Cdc42
are shown. (B) Cells were treated with DMSO (Veh) or resveratrol at 5 or 50 M for 2, 5, 10, or 30 minutes. Cells were lysed immediately and used for pull-down
assays to determine endogenous Cdc42 activity. Representative Western blot analyses of active and total Cdc42 levels from three separate experiments are
shown. (C) Cdc42 activity (active Cdc42/total Cdc42) relative to vehicle (Veh) as quantified from densitometric scans of Western blot analyses. *Statistical
significance from control at P V .05. Error bars represent SEMs from at least three experiments. n = 2 for 2, 5, or 30 minutes, and n = 6 for 10 minutes in treatments
with 50 M resveratrol.
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Treatment with 50 mM resveratrol did not affect lamelli-
podia extension in control or Rac1(T17N)–expressing cells,
but instead showed a filopodia response in both cell lines.
Cells expressingRac1(T17N) responded to 50 mMresveratrol
by filopodia extension similar to the control vector (Figure 6,B
and D), and these responses were significant from con-
trol vehicles for both cell lines (both P < .001). Estrogen or
EGF treatment of control cells expressing vector alone or a
dominant-negative Rac1 did not cause extension of filopodia.
Because 50 mM resveratrol inhibits Rac activity, this may
contribute to the global and sustained induction of filopodia
without subsequent conversion to lamellipodia.
Discussion
This investigation extends our studies on the disparate roles
of estrogen and 50 mM resveratrol in cell migration and in
the extension of cell surface actin structures in metastatic
breast cancer cells. As we have shown previously, the data
presented herein demonstrate that 50 mM resveratrol induces
a unique actin morphology through the rapid extension of
unpolarized filopodia [2]. Therein, we hypothesized that
the observed decreased migration and invasion by 50 mM
resveratrol are due to this phenotype of sustained filopodia.
Subsequent studies have also shown inhibition of invasion
by high concentrations of resveratrol (50–100 mM), with po-
tential additional mechanisms for resveratrol-mediated inhi-
bition of invasion. Resveratrol at high concentrations has
been shown to inhibit MMP-2 and MMP-9 activity, to increase
tensin expression, and to inhibit Jun kinase and protein
kinase C to, in turn, inhibit cancer cell invasion [18,20,21,33].
We report an interesting effect of a low concentration and a
high concentration of resveratrol on cell migration in ERa()
ERb(+) MDA-MB-231 cells. At a low concentration, 5 mM
resveratrol increases cell migration and invasion, whereas
50 mM resveratrol inhibits cell migration and invasion. This
kind of concentration-dependent biphasic effect of resver-
atrol has been shown in numerous models and may be
attributed to the mixed ER agonist/antagonist properties
of this structurally similar phytosterol. It is often the case
that lower concentrations (0.01–10 mM) of resveratrol act
in an estrogenic manner to activate pathways such as MAPK
or PI3-K/Akt, whereas higher concentrations (50–100 mM)
inhibit them [8–10,34–36]. We have not observed any
changes in cell cycle progression at 8 hours following 50 mM
resveratrol; however, MDA-MB-231 cells undergo apoptosis
at 24 to 48 hours following treatment with 50 mM resveratrol
(data not shown). Therefore, the well-established effects
of resveratrol on apoptotic pathways [8,10–12,21] may also
contribute to the inhibition of cell migration and invasion by
50 mM resveratrol.
We show that resveratrol has opposing concentration-
dependent effects on actin cytoskeletal morphology, which
is hypothesized to contribute directly to differential effects
on migration. Resveratrol at 5 mM induces a rapid, sustained,
leading-edge lamellipodia in the same manner as estrogen
and EGF. MDA-MB-231 cells stimulated with EGF, estrogen,
or 5 mM resveratrol first form filopodia, which are rapidly
converted to lamellipodia. Conversely, resveratrol at 50 mM
induces a rapid, unpolarized, and sustained filopodia re-
sponse even up to 8 hours in serum or ECMmatrices. These
data indicate that the maintenance of a nonmigratory pheno-
type by 50 mM resveratrol may be directly correlated with
50-mM resveratrol– induced filopodia that do not get con-
verted to lamellipodia, which are useful for cell migration.
Directed cell migration involves themodulation of the actin
cytoskeleton byRhoGTPases—a family of signaling proteins
with 22members [37]. Themost characterized RhoGTPases
Rho, Rac, and Cdc42 have been classically implicated in
the reorganization of the actin cytoskeleton to form stress
fibers, lamellipodia, and filopodia, respectively, and these
three proteins are thought to act coordinately to regulate cell
migration and, thus, invasion and metastasis [26,29,31,38].
Recent studies have implicated Rho proteins specifically
in the promotion of breast cancer metastasis [29,39–41].
Studies have shown the importance of Rho isoforms A and C
in breast cancer [29,39,42]. We and others have shown
that Rac and Cdc42 are also important regulators of breast
cancer metastasis [30,40,43]. Cdc42 activation by growth
factor receptor signaling often leads to Rac activation and,
thus, the reorganization of filopodia into lamellipodia
[26,44,45]. Rac signaling to extend lamellipodia at the lead-
ing edge and subsequent cell migration away from the
primary tumor have been specifically linked to the regulation
of breast cancer metastasis [29,41,45].
Because filopodia and lamellipodia have been shown
to be primarily under Rac and Cdc42 regulation, we focused
the present investigation on the role of estrogen and resver-
atrol signaling to Rac and Cdc42. Our novel data reveal that
resveratrol affects Rac and Cdc42 activity in MDA-MB-231
metastatic breast cancer cells differently, depending on
concentration. The peak filopodia response to 50 mM resver-
atrol (10 minutes) can be correlated with the time of 50-mM
resveratrol– induced inhibition of Rac and Cdc42 activity.
Cdc42 activation generally leads to a transient polarized
filopodia extension, followed by Rac activation and the sub-
sequent conversion of filopodia into motile lamellipodia [31].
The 50-mM resveratrol– induced decrease in Cdc42 activity
may indicate that Cdc42 may be primarily responsible for the
polarization of MDA-MB-231 cells, and resveratrol-mediated
inhibition of Cdc42 may contribute to global and sustained
filopodia response to 50 mM resveratrol by inhibiting sub-
sequent Rac activation that would lead to the conversion of
filopodia into leading-edge lamellipodia. Contrary to our
results with breast cancer cells, a study using leukemia cells
showed that 20 mM resveratrol activated Cdc42 at 30 and
60 minutes to induce apoptosis through a Jun N-terminal/
FasL signaling pathway [46]. This result may be a cell type–
specific effect of resveratrol on leukemia cells.
Interestingly, when MDA-MB-231 cells stably expressing
dominant-negative Cdc42 were treated with 50 mM resvera-
trol, there was partial reduction of filopodia. Therefore, a
transient increase in Cdc42 activity may be responsible for
an initial extension of filopodia. However, as shown by our
results, resveratrol (50 mM) decreased Cdc42 activity at
times as low as 2 minutes following addition. Therefore, the
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observed induction of filopodia by resveratrol may be largely
independent of Cdc42 and may be under the regulation of
alternative filopodia-associated Rho GTPases such as Rif
and/or Wrch-1 [47,48]. It is also possible that the 50-mM
resveratrol–mediated signaling pathway bypasses Cdc42
and directly signals to a downstream effector such as WASP
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[49]. Thus, these results indicate that resveratrol modu-
lation of the actin cytoskeleton may involve novel Cdc42-
independent mechanisms that implicate other Rho GTPases
or the direct activation of downstream effectors of Cdc42.
We have shown that treatment of MDA-MB-231 cells with
EGF or estrogen resulted in a motile phenotype of increased
lamellipodia and associated focal adhesions at the leading
edge [2]. This estrogen-induced effect on lamellipodia forma-
tion has also been observed in endothelial, breast cancer,
and endometrial cancer cells [2–5]. Such estrogen-induced
membrane ruffles in ERab(+)MCF-7 breast cancer cells have
been shown to colocalize withmembrane ERa [28]. Recently,
estrogen-induced lamellipodia formation and focal adhesion
assembly of endothelial cells correlated with a G protein–
coupled mechanism that signaled to Rho and Rho kinase [5].
Our data indicate a strong role for Rac in the extension of
lamellipodia and in subsequent increases in breast cancer
cell migration and invasion in response to estrogen and low
concentrations of resveratrol. We demonstrate that low con-
centrations of resveratrol (5 mM) act in a manner similar to
EGF and estrogen and induce Rac activity and lamellipodia
extension at 10 minutes. Moreover, lamellipodia response to
EGF, estrogen, or 5 mM resveratrol can be completely abol-
ished by inhibition of Rac activity using cells expressing
dominant-negative Rac.
The reported increase in Rac activity and migratory
phenotype in response to estrogen and a low concentration
of resveratrol elucidates a novel mechanism by which estro-
gen and resveratrol can promote breast cancer progression.
An important finding is that resveratrol at low concentrations
elicits signaling that may promote cell migration/invasion,
whereas resveratrol at high concentrations may inhibit these
signaling pathways. We hypothesize that inhibition of Rac
and Cdc42 activities leading to sustained and unpolarized
filopodia formation and subsequent inhibition of cell migration
and invasion by 50 mM resveratrol may lead to reduced breast
cancer metastasis. Overall, these data indicate that resver-
atrol can act as a breast cancermetastasis–preventive agent
but should be used with caution with regard to concen-
tration. Even though such high concentrations may not be
Figure 5. Rac activity of breast cancer cells in response to estrogen or resveratrol. Quiescent MDA-MB-231 cells were treated with DMSO (Veh), 50 ng/ml EGF,
0.1 M estrogen (E2), or resveratrol (Res). PAK–PBD–GST beads were used to pull down active GTP-bound Rac from cell lysates. Active and total Rac levels
were detected by Western blot analysis with anti-Rac antibody. (A) Representative Western blot analysis of the Rac activity of MDA-MB-231 cells in response to
vehicle, EGF, E2, or resveratrol at 5 or 50 M following a 10-minute incubation. Results shown are representative of at least three experiments. (B) Rac activity
(active Rac/total Rac) relative to vehicle-alone control as quantified from densitometric scans of Western blot analyses. *Statistical significance from control. Error
bars represent SEMs from at least three experiments. n = 2 for 30 or 60 minutes in 5 M resveratrol, and n = 2 for 5, 20, 30, or 60 minutes in 50 M resveratrol.
Figure 4. Effect of a stable expression of a dominant-negative Cdc42(T17N) on resveratrol-mediated filopodia extension. (A) Representative Western blot analysis
of MDA-MB-231 cells stably expressing vector or myc-tagged Cdc42. (B) Filopodia extension in response to resveratrol in cells expressing vector alone or
Cdc42(T17N). Quiescent MDA-MB-231 cells expressing a control vector (control) or myc-tagged Cdc42(T17N) were treated with vehicle (Veh), 400 ng/ml
bradykinin (Brady), or 50 M resveratrol (Res), then fixed and stained for F-actin with rhodamine phalloidin. Representative cells of at least 100 cells/treatment are
shown. Arrowheads indicate filopodia. (C) Quantification of the effect of the stable expression of a dominant-negative Cdc42(T17N) on resveratrol-mediated
filopodia extension. Quiescent MDA-MB-231 cells expressing a control vector (dark-grey columns) or Cdc42(T17N) (light-grey columns) were treated with vehicle,
400 ng/ml bradykinin, or 50 M resveratrol, then fixed and stained for F-actin with rhodamine phalloidin. The relative number of filopodia per cell (± SEM) was
quantified from micrographs for at least 100 cells/treatment. Treatments denoted by the same letter indicate no significant difference between those treatments.
Treatments denoted by different letters indicate a significant difference between those treatments at P V .05.
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Figure 6. Effect of a stable expression of a dominant-negative Rac on estrogen-mediated actin structures. (A) RepresentativeWestern blot analysis of MDA-MB-231
cells stably expressing vector (control) or myc-tagged Rac. (B) Actin structures in response to resveratrol in cells expressing Rac1(T17N). Quiescent MDA-MB-231
cells expressing vector (control) or myc-tagged Rac1(T17N) were treated with vehicle (UN), 50 ng/ml EGF, 0.1 M estrogen (E2), 5 or 50 M resveratrol (Res), then
fixed and stained for F-actin with rhodamine phalloidin. Representative cells of at least 100 cells/treatment are shown. Arrows indicate lamellipodia; arrowheads
indicate filopodia. (C and D) Quiescent MDA-MB-231 cells expressing a control vector (dark-grey columns) or Rac1(T17N) (light-grey columns) were treated with
vehicle (Veh), 50 ng/ml EGF, 0.1 Mestrogen (E2), or 5 or 50 M resveratrol (Res), then fixed and stained for F-actin with rhodamine phalloidin. The relative number of
lamellipodia per cell (± SEM) quantified from micrographs for at least 100 cells/treatment (C). The relative number of filopodia per cell (± SEM) quantified from
micrographs for at least 100 cells/treatment (D). Treatments denoted by the same letter indicate no significant difference between those treatments. Treatments
denoted by different letters indicate a significant difference between those treatments at P V .05.
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achieved by consumption of foods containing resveratrol,
pharmacological concentrations of resveratrol may have
breast cancer–preventive/therapeutic potential. Therefore,
this disparate unique mechanism of action of a common
dietary compound at low and high concentrations directly
impacts the use of resveratrol in breast cancer prevention
and therapy.
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